Anup Marda
Vermogen: 189 000 $ op 31-05-2026
Vermogen: 189 000 $ op 31-05-2026
Anup Marda is currently Chief Financial & Accounting Officer at Cabaletta Bio, Inc. since 2019.
Formerly, Mr. Marda was Executive Director at US Pharmaceuticals, Inc. from 2012 to 2014 and VP, Head-Global Financial Planning & Analysis at Bristol Myers Squibb Co. from 2018 to 2019.
Education includes an undergraduate degree from Indian Institute of Technology Bombay and an MBA from Krannert School of Management.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CABALETTA BIO, INC. 0,05% | 02-03-2026 | 50.000 ( 0,05% ) | 189 000 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CABALETTA BIO, INC. | Financieel Directeur/CFO | 01-01-2019 |
| Bedrijven | Functie | Einde |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-01-2019 |
US Pharmaceuticals, Inc.
US Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes medicines | Directeur/Bestuurslid | 01-01-2014 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
US Pharmaceuticals, Inc.
US Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes medicines | Health Technology |
Indian Institute of Technology Bombay
Indian Institute of Technology Bombay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Krannert School of Management
Krannert School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which discovers and develops engineered cell therapies for B cell-mediated autoimmune diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau